• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • English
    • Français
  • Canada
    • Sandoz Site Directory
Sandoz : A Novartis Division
  • Our Work
    • What We Do
    • Quality Generics
    • Biopharmaceuticals
    • Specialty Products
  • About Us
    • Who We Are
    • Corporate Responsibility
    • Doing Business Responsibly
    • Contact Us
    • Grants, Donations and Sponsorships
  • Products
    • Consumers
    • Patients
    • Healthcare Professionals
    • Patient Support Programs
  • News
    • Media Releases
    • Media Resource Center
    • Stay Up-To-Date
  • Careers
    • Available Positions
    • Join the Sandoz Manufacturing team in Boucherville
    • Our Benefits
    • Employee Testimonials
    • Our Values and Vision
    • Diversity & Inclusion
Search
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
  • Jump to Comments
Stories/Global Impact

Important update about the Boucherville plant and development center acquired by Avara

Jul 25, 2019

It is with great satisfaction that we are now advising that the Superior Court of Quebec decided to grant Sandoz Canada the right to buy back the Boucherville site, which has been under receivership as an interim measure to maintain continued operations. The anticipated transaction will be concluded with the Receiver within a few months. We believe we are currently best positioned to supply without interruption the hospitals in Canada and USA with the products they need for their patients.

Sandoz Canada is committed to bringing stable operations management back in the site, as well as the support and rewarding work environment the employees need as they continue to work on producing Sandoz high-quality, injectable medicines Canadian patients, their healthcare professionals and our customers rely on. We are considering the possibility of selling the site in the future to a qualified buyer in order to ensure its long-term sustainability.

 

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Global Impact

Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz® (adalimumab)

Global Impact

Sandoz Canada launches the first generic versions of two original drugs: PrSandoz® Posaconazole and PrSandoz® Silodosin

Global Impact

2021 Top Employer Canada

You are here

  1. Home ›
  2. Global Impact ›

Sandoz Canada

  • Our Work
  • About Us
  • Products
  • News
  • Careers
  • Contact Us
  • Office Locations
  • Stay up to date

Subscribe to Sandoz

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • RSS
  • Sandoz Site Directory
© 2021 Sandoz AG

This site is intended for an audience in Canada

  • Terms of Use
  • Privacy Policy
  • Terms of Trade
  • Return Policy